WS Investor
10 Nov 2026, 15:54
Liquidia Slips 0.25% as YUTREPIA Sales Surge but Litigation Settlement Drives Large Net Loss
Liquidia (NASDAQ: LQDA) shares slipped about 0.25% after the company reported strong YUTREPIA sales growth and improving adjusted profitability, while a large litigation settlement drove a substantial GAAP net loss.
Third-quarter YUTREPIA net product sales reached $222.7 million, up 31% sequentially and more than fourfold from $51.7 million a year earlier. Patient shipments reached a record monthly level in October, referral-to-start conversion remained above 87%, and the prescriber base expanded to 1,300.
Excluding settlement-related charges, operating momentum remained strong. Liquidia posted its fifth consecutive quarter of higher non-GAAP adjusted EBITDA, reaching $140.5 million.
However, the company recorded a $389.7 million litigation settlement charge, resulting in a quarterly net loss of $236.3 million, or $2.64 per share. The global settlement with United Therapeutics requires net payments of $380.7 million across 2026 and 2027 and also removes the PH-ILD indication from YUTREPIA’s label.
Liquidia ended September with $396.1 million in cash and cash equivalents before settlement payments and continues to advance additional YUTREPIA and L606 programs.
The modest 0.25% decline appears to reflect the financial impact and strategic consequences of the settlement, partly offset by very strong YUTREPIA commercial growth and continued improvement in adjusted profitability.
Liquidia (NASDAQ: LQDA) shares slipped about 0.25% after the company reported strong YUTREPIA sales growth and improving adjusted profitability, while a large litigation settlement drove a substantial GAAP net loss.
Third-quarter YUTREPIA net product sales reached $222.7 million, up 31% sequentially and more than fourfold from $51.7 million a year earlier. Patient shipments reached a record monthly level in October, referral-to-start conversion remained above 87%, and the prescriber base expanded to 1,300.
Excluding settlement-related charges, operating momentum remained strong. Liquidia posted its fifth consecutive quarter of higher non-GAAP adjusted EBITDA, reaching $140.5 million.
However, the company recorded a $389.7 million litigation settlement charge, resulting in a quarterly net loss of $236.3 million, or $2.64 per share. The global settlement with United Therapeutics requires net payments of $380.7 million across 2026 and 2027 and also removes the PH-ILD indication from YUTREPIA’s label.
Liquidia ended September with $396.1 million in cash and cash equivalents before settlement payments and continues to advance additional YUTREPIA and L606 programs.
The modest 0.25% decline appears to reflect the financial impact and strategic consequences of the settlement, partly offset by very strong YUTREPIA commercial growth and continued improvement in adjusted profitability.
